[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"probiotic-intervention\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:probiotic-intervention":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,41,62,97,125,152,179,201],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100634447","phase-2-efficacy-and-safety-of-sertraline-combined-with-lactobacillus-crispatus-in-adolescents-with-depression-100634447",false,"NCT07539805","Efficacy and Safety of Sertraline Combined With Lactobacillus Crispatus in Adolescents With Depression","Efficacy and Safety of Sertraline Combined With Lactobacillus Crispatus in Adolescents With Depression : A Multicenter Randomized Controlled Trial","Inclusion criteria\n\n* Aged 12-18 years\n* Meets DSM-5 criteria for major depressive disorder (MDD) and is currently in a depressive episode according to the Kiddie Schedule for Affective Disorders and Schizophrenia - Present and Lifetime Version (K-SADS-PL) interviews\n* Child Depression Rating Scale-Revised (CDRS-R) score ≥40 at baseline\n* Clinical Global Impression Scale (CGI-S) score ≥ 4 at baseline\n\nExclusion criteria\n\n* Presence of any comorbid psychiatric disorder according to DSM-5, other than anxiety disorders\n* MDD with psychotic symptoms\n* Young Mania Rating Scale (YMRS) \\>13 at baseline\n* History of neurological disorders (e.g., epilepsy, traumatic brain injury), or the presence of serious physical illnesses (e.g., thyroid disease, lupus erythematosus, diabetes mellitus, clinically significant pulmonary, hepatic, or renal impairment, or major trauma)\n* Nonresponse to at least two antidepressants with different mechanisms, and each administered at an adequate dose and for an adequate duration\n* History of intolerance to sertraline or nonresponse to an adequate therapeutic course of sertraline\n* Current high suicide risk\n* History of alcohol or drug abuse or dependence\n* Taking or administering antidepressants within 5 half-lives\n* Use of probiotic-related food or medicine within 2 weeks before enrollment\n* Systemic use of antibiotics or antifungals within 1 month before enrollment\n* History of severe food allergy or known hypersensitivity to the Lactobacillus crispatus preparation or any of its components\n* Adherence to vegetarian or other restrictive dietary patterns\n* Pregnancy or breastfeeding","ALL","12 Years","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this clinical trial is to evaluate the efficacy and safety of sertraline combined with Lactobacillus crispatus in adolescents aged 12-18 years with major depressive disorder. The main question it aims to answer is: Whether sertraline combined with Lactobacillus crispatus is superior to sertraline combined with placebo in reducing depressive symptoms and improving emotional symptoms in adolescents with depression.\n\nIf there is a comparison group: Researchers will compare sertraline combined with Lactobacillus crispatus with sertraline combined with placebo ( look-alike substance that contains no probiotics) to determine whether the addition of Lactobacillus crispatus provides greater therapeutic benefit in adolescents with depression.\n\nParticipants will: 1. Receive sertraline combined with Lactobacillus crispatus or sertraline combined with placebo for 8 weeks; 2. Attend clinic visits every 4 weeks for clinical assessments and safety monitoring",[27,28],"Major Depressive Disorder (MDD)","Probiotic Intervention","RECRUITING","2026-06-11",{"date":32,"type":33},"2026-06-15","ACTUAL",{"date":30,"type":33},{"date":36,"type":21},"2028-04",{"name":38,"class":39},"First Affiliated Hospital of Chongqing Medical University","OTHER",2,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},"100643411","phase-2-sertraline-combined-with-multi-strain-probiotics-for-adolescent-depression-100643411","NCT07645157","Sertraline Combined With Multi-Strain Probiotics for Adolescent Depression","A Study on the Efficacy and Safety of Sertraline Combined With Multi-Strain Probiotics in Treating Adolescent Patients With Depression: A Multi-Center Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* • Aged 12-18 years\n\n  * Meets DSM-5 criteria for major depressive disorder (MDD) and is currently in a depressive episode according to the Kiddie Schedule for Affective Disorders and Schizophrenia - Present and Lifetime Version (K-SADS-PL) interviews\n  * Child Depression Rating Scale-Revised (CDRS-R) score ≥40 at baseline\n  * Clinical Global Impression Scale (CGI-S) score ≥ 4 at baseline\n\nExclusion Criteria:\n\n* • Presence of any comorbid psychiatric disorder according to DSM-5, other than anxiety disorders\n\n  * MDD with psychotic symptoms\n  * Young Mania Rating Scale (YMRS) \\>13 at baseline\n  * History of neurological disorders (e.g., epilepsy, traumatic brain injury), or the presence of serious physical illnesses (e.g., thyroid disease, lupus erythematosus, diabetes mellitus, clinically significant pulmonary, hepatic, or renal impairment, or major trauma)\n  * Nonresponse to at least two antidepressants with different mechanisms, and each administered at an adequate dose and for an adequate duration\n  * History of intolerance to sertraline or nonresponse to an adequate therapeutic course of sertraline\n  * Current high suicide risk\n  * History of alcohol or drug abuse or dependence\n  * Taking or administering antidepressants within 5 half-lives\n  * Use of probiotic-related food or medicine within 2 weeks before enrollment\n  * Systemic use of antibiotics or antifungals within 1 month before enrollment\n  * History of severe food allergy or known hypersensitivity to the Lactobacillus crispatus preparation or any of its components\n  * Adherence to vegetarian or other restrictive dietary patterns\n  * Pregnancy or breastfeeding",{"count":49,"type":21},120,[24],"The objective of this clinical trial is to evaluate the efficacy and safety of sertraline combined with multi-strain probiotics in adolescents aged 12-18 with major depressive disorder. The primary research question is whether sertraline combined with multi-strain probiotics is superior to sertraline combined with placebo in alleviating depressive symptoms and improving mood symptoms in adolescents. If there is a control group: researchers will compare sertraline combined with multi-strain probiotics with sertraline combined with placebo (a substance that looks similar but does not contain probiotics) to determine whether adding multi-strain probiotics provides greater therapeutic benefits for adolescent patients with depression. Participants will: 1. Undergo 8 weeks of treatment with sertraline combined with multi-strain probiotics or sertraline combined with placebo; 2. Have clinical visits every 4 weeks for clinical assessments and safety monitoring.",[27,28],"2026-06-09",{"date":55,"type":33},"2026-06-12",{"date":57,"type":21},"2026-10-01",{"date":59,"type":21},"2028-10-01",{"name":38,"class":39},1,{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":69,"sex":16,"minAge":70,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":22,"phases":73,"briefSummary":75,"conditions":76,"keywords":81,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":4},"100634321","food-trial-evaluating-fecal-abundance-of-sbd111-with-once-daily-versus-twice-daily-administration-in-healthy-adults-100634321","NCT07538167","Food Trial Evaluating Fecal Abundance of SBD111 With Once-Daily Versus Twice-Daily Administration in Healthy Adults","An Open-Label, Randomized, Parallel-Arm Food Trial Evaluating Fecal Abundance of SBD111 With Once-Daily Versus Twice-Daily Administration in Healthy Adults","Inclusion Criteria:• Provide written informed consent.\n\n* Stated availability throughout entire study period and willingness to fulfill all details of the protocol.\n* Age 35 years or older.\n* Be in general good health as determined by a screening evaluation within 30 days of the first administration of SBD111 medical foods.\n* Willing to comply with protocol and report on compliance and side effects during study period.\n* Body Mass Index between 18.5 and 40kg\u002Fm2.\n\nExclusion Criteria:\n\n* • Are currently taking probiotic or prebiotic supplements or have taken them in the past 30 days. If participant is willing to stop taking probiotic or prebiotic supplement for 30-days, they can be re-screened for eligibility and enrollment after consent.\n\n  * Unwilling to avoid probiotics\u002Fprebiotics supplements for the duration of the study.\n  * Known or suspected allergies to probiotics, maltodextrin, or berries.\n  * Received oral or parenteral antibiotics within 30 days of enrollment or prescribed antibiotics on the day of enrollment.\n  * Major surgery on the intestines or endoscopy within last 3 months.\n  * History of drug and\u002For alcohol abuse at the time of enrollment.\n  * Presence of any of the following based on participant reported health history:\n  * Clinically significant systems abnormalities based on screening questionnaire.\n  * Indwelling catheter or feeding tube.\n  * Febrile illness (oral temperature \\>37 degrees Celsius) or one or more episodes of diarrhea within 72 hours of baseline (first administration of study article).\n  * Active bowel leak, acute abdomen, colitis, or active GI disease or history of gastric or intestinal dysmotility, slowed transit time, variable small intestinal permeability, pancreatitis, or inflammatory bowel disease.\n  * History of Hepatitis B or Hepatitis C infections, cirrhosis, or chronic liver disease.\n  * Underlying structural heart disease or previous history of endocarditis or valve replacement.\n  * Immunosuppression including HIV positive, solid organ or stem cell transplant recipient, receiving any oral or parenteral immunosuppressive therapy.\n  * History of Celiac disease.\n  * History of cancer.\n\n    a. Excluding non-melanoma skin cancers or cancer more than 10 years ago.\n  * History of autoimmune disease and taking any immunosuppressant drugs.\n  * Active tuberculosis.\n  * Pregnant, planning on becoming pregnant within the next 2 months, breastfeeding, positive urine pregnancy test within 24 hours of first administration of DMA.\n  * Participants may be excluded if, in the investigator's opinion, there is evidence of cognitive impairment or dementia which is sufficient to interfere with informed consent or adherence to the study protocol. Four questions will be asked during the informed consent process to confirm participant's understanding and ability to comply. (See section 8.3)\n  * Any other condition that in the opinion of the investigator would jeopardize the safety or rights of the volunteer participating in the study or would make it unlikely the volunteer could complete the study.\n  * Bowel movement frequency less than one per 36-hour period.\n  * If the subject has been in a recent experimental trial, these must have been completed not less than 30 days prior to this study.",true,"35 Years",{"count":72,"type":21},80,[74],"NA","The purpose of this study is to determine whether a modified formulation and daily intake schedule of SBD111 results in similar levels of probiotic microbes in the gut compared with the currently used formulation. SBD111 is a food made of probiotic microbes (bacteria and yeast) and prebiotic dietary fibers (a form of fiber obtained from diet). SBD111 is a medical food used for the dietary management of postmenopausal bone loss.SBD111 was previously found to be safe and well tolerated in a human clinical safety study and a clinical efficacy study. Study participation will include a screening virtual visit, periodic remote questionnaires and check-in calls, and three at-home stool swab sample collections.\n\nEligible participants will be assigned to one of two SBD111 study groups evaluating different formulations and dosing schedules. Each day for a 28-day period, they will take (i) two capsules once daily or (ii) two capsules twice daily (morning and evening), depending on the study group assigned. Investigators will collect demographic information and will ask questions related to dietary intake, bowel habits, and health history. Upon enrollment into the study, participants will receive six at-home stool sample collection kits, two each for baseline, Week 1, and Week 4 analysis. Samples will be collected at home and mailed to a Sōlaria Biō for analysis of the bacterial community that lives in the intestine (the gut microbiome). During the study, participants will also be asked to complete brief questionnaires related to gastrointestinal symptoms, cognitive function, well-being, and sleep. On days 7 and 28 of the study, they will be asked to complete a brief adherence questionnaire and discuss any adverse (negative) events.\n\nAll participants will receive compensation in the form of gift cards for completing study procedures and returning stool samples. Participants will receive a $50.00 gift card after completing the Week 1 study procedures and after receipt of the mailed baseline and Day 7 stool swab samples. Participants will receive a $150.00 gift card after completing the Week 4 study procedures and after receipt of the mailed Week 4 stool swab sample.",[77,78,79,28,80],"Osteopenia","Osteoporosis","Menopause Related Conditions","Synbiotics",[82,83,84,77,78,85],"Probiotic","Synbiotic","Bone Loss","Fully Remote","NOT_YET_RECRUITING","2026-04-15",{"date":89,"type":33},"2026-04-20",{"date":91,"type":21},"2026-04",{"date":93,"type":21},"2027-02",{"name":95,"class":96},"Solarea Bio, Inc","INDUSTRY",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":69,"sex":105,"minAge":18,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":112,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":61},"100632351","probiotic-research-on-safety-palatability-efficacy-and-receptivity-100632351","NCT07512557","Probiotic Research On Safety, Palatability, Efficacy and Receptivity","Evaluating the Effectiveness and Feasibility of a Probiotic Intervention to Improve Nutrient Levels in Reproductive-Aged Women: A Pilot Study","PROSPER","Inclusion Criteria:\n\n* Non-pregnant and non-lactating\n* English speaking with the ability to give informed consent\n* 18-40 years of age (inclusive)\n* Women who are biologically female\n* Willing and able to agree to the requirements and lifestyle restrictions of this study\n* Able to understand and read the questionnaires in English and carry out all study-related procedures\n* Located in the greater Ottawa area and a resident of Ontario\n\nExclusion Criteria:\n\n* Individuals who are lactating, pregnant, or planning to become pregnant during the study\n* Individuals who are not maintaining adequate birth control measures\n* Adequate birth control measures include any option that will adequately prevent pregnancy including: contraceptives, lifestyle choices, complete abstinence, or as a result of other medical methods, procedures, or conditions\n* Have a known sensitivity, intolerability, or allergy to any of the study products or their excipients\n* Are using vitamin and mineral supplements containing B vitamins\n* Intake of a B-vitamin-containing micronutrient supplement or probiotic product in the previous 4 weeks\n* Expecting to change diet and exercise regimen in the next 4 weeks\n* Have planned surgery during the course of the study\n* Use of investigational product(s) in another research study within 30 days prior to the baseline visit or during the study duration\n* Taking probiotics during the study period\n* More than 2 alcoholic beverages per day throughout the duration of the study\n* Known medical history of specific conditions including: Gastrointestinal disorders: celiac disease, ulcerative colitis, and Crohn's disease; Gastric cancer and gastric polyps; Inflammatory bowel diseases; Helicobacter pylori infection; Gastrectomy, duodenal bypass, bariatric surgery","FEMALE","40 Years",{"count":108,"type":21},82,[74],"The goal of this pilot study is to determine if taking a commercially available probiotic product can influence levels of vitamins B12, B6 and folate after a 4-week supplementation period in reproductive-aged women without any micronutrient deficiencies. The main question it aims to answer is:\n\n• Does a probiotic product influence blood folate, vitamin B12 and B6 levels in reproductive-aged women when it is taken regularly for 4 weeks?\n\nParticipants in this clinical trial will consume the probiotic product containing multiple probiotic strains regularly for 4 weeks. One group will consume one capsule per day at a particular dose, and the second group will consume two capsules per day at another dose. Participants will also have to:\n\n* Attend two in-person visits with a researcher: at enrolment (baseline), and endline (day 28\u002F4 weeks)\n* Provide a blood sample at baseline (day 0) and endline (day 28\u002F4 weeks)\n* Provide two stool samples (following each in-person visit)\n* Complete an online \"study diary\" every two weeks for 4 weeks (2 study diaries)\n* Complete two sets of online questionnaires (following each in-person visit)\n* Complete two sets of dietary assessments (following each in-person visit)",[28],[113,114,115],"B vitamins","Reproductive-aged women","Probiotics","2026-04-01",{"date":118,"type":33},"2026-04-06",{"date":120,"type":33},"2025-11-28",{"date":122,"type":21},"2026-07-30",{"name":124,"class":39},"Carleton University",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":69,"sex":16,"minAge":132,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":136,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":61},"100592111","probiotic-intervention-on-body-weight-100592111","NCT06989177","Probiotic Intervention on Body Weight","An Interventional Study Investigating the Effects of Probiotics on Body Weight and Metabolic Homeostasis","Inclusion Criteria:\n\n* Aged 20 to 50 years.\n* Normal-weight participants: 18.5 kg\u002Fm² ≤ Body Mass Index (BMI) \\\u003C 24 kg\u002Fm².\n* Overweight or obese participants:\n\nBMI ≥ 28 kg\u002Fm², or 24 kg\u002Fm² ≤ BMI \\\u003C 28 kg\u002Fm² and a clinical diagnosis meeting semaglutide treatment indications (e.g., hyperglycemia, hypertension, dyslipidemia, fatty liver, obstructive sleep apnea, cardiovascular disease, etc.).\n\n* Willingness to participate in this study and provide signed informed consent.\n\nExclusion Criteria:\n\n* Abnormal metabolic indicators (meeting any one of the following criteria is grounds for exclusion):\n\n  1\\. Normal weight (18.5 kg\u002Fm² ≤ BMI \\\u003C 24 kg\u002Fm²):\n  1. Waist circumference ≥ 90 cm for men or ≥ 85 cm for women.\n  2. Fasting glucose ≥ 6.1 mmol\u002FL or 2-hour postprandial glucose ≥ 7.8 mmol\u002FL, or a confirmed diagnosis of diabetes.\n  3. Systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg, or currently under antihypertensive treatment.\n  4. Fasting triglycerides (TG) ≥ 1.7 mmol\u002FL; high-density lipoprotein cholesterol (HDL-C) \\\u003C 0.9 mmol\u002FL in men or \\\u003C 1.0 mmol\u002FL in women.\n\n  2\\. Overweight or obese (BMI ≥ 24 kg\u002Fm²):\n  1. Fasting plasma glucose \\> 11.1 mmol\u002FL or HbA1c \\> 9%, or previously diagnosed diabetes, or currently using insulin or any antidiabetic medication.\n  2. Blood pressure ≥ 160\u002F100 mmHg, or clinically diagnosed stage 2 or stage 3 (moderate or severe) hypertension, or currently under antihypertensive treatment.\n  3. Use of lipid-lowering drugs (e.g., fibrates, bile acid sequestrants, statins, PCSK9 inhibitors) within the past 3 months, or TG ≥ 5.7 mmol\u002FL, or LDL ≥ 4.9 mmol\u002FL.\n* Pregnancy or lactation.\n* Self-reported weight change of more than 5 kg within the 90 days prior to screening.\n* Use of antibiotics, antimicrobials, or anti-inflammatory\u002Fanalgesic salicylates (e.g., aspirin) within the 3 months prior to screening for 3 days or more.\n* Use of estrogen therapy or other hormonal medications within the past 6 months.\n* Use of GLP-1 receptor agonists or probiotics within the past 3 months.\n* Heavy alcohol consumption (females \\> 40 g\u002Fday, approximately 250 mL of huangjiu \\[yellow rice wine\\], or 1000 mL of beer, or 100 mL of liquor per day; males \\> 80 g\u002Fday).\n* Severe liver or kidney dysfunction (ALT, AST, or serum creatinine exceeding 3 times the upper limit of normal, UACR ≥ 30 mg\u002Fg, or eGFR \\\u003C 60 mL\u002Fmin).\n* Gastrointestinal diseases affecting digestion and absorption (e.g., severe diarrhea, severe constipation, severe inflammatory bowel disease, peptic ulcer, gallstones, cholecystitis).\n* Underwent surgery within the past year (excluding appendectomy or hernia repair).\n* Severe cardiovascular or cerebrovascular diseases (e.g., heart failure, myocardial infarction, stroke, acute myocarditis, severe arrhythmia, or receiving interventional therapy).\n* Presence of metallic implants such as a cardiac stent or pacemaker.\n* Cancer or having received radiation or chemotherapy within the past 5 years.\n* Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia, or a personal history of hyperthyroidism or hypothyroidism.\n* Chronic or acute pancreatitis.\n* Positive hepatitis B surface antigen (HBsAg), active tuberculosis, HIV, or other infectious diseases.\n* Currently participating in another clinical study or having done so within the past 3 months.\n* Claustrophobia.\n* Any psychiatric disorder such as attention-deficit\u002Fhyperactivity disorder (ADHD), bipolar disorder, or epilepsy (including current use of antiepileptic medications), or use of antidepressant medications.\n* Inability to read, write, operate a smartphone, or perform daily activities independently.","20 Years","50 Years",{"count":135,"type":21},140,[74],"This study is a randomized controlled trial with 120 overweight or obese (body-mass index, BMI, ≥ 24 kg\u002Fm²) participants and 20 normal-weight participants. Twelve weeks of energy-restricted nutritional and lifestyle intervention with placebo, Lactobacillus paracasei LC-19 (LC-19), or semaglutide (a glucagon-like peptide-1 receptor agonist, GLP-1RA) will be randomly conducted in the overweight or obese participants. The primary goal is to clarify the roles of LC-19 and semaglutide in weight reduction and in improving energy, glucose, and lipid metabolism, while also comparing side effects, adverse events, and long-term outcomes such as weight regain between these two interventions. In addition, the study will explore key factors affecting intervention response to provide evidence for optimizing individualized intervention strategies.",[139,140,141,28],"Obesity","Homeostasis","Weight Loss","2026-03-16",{"date":144,"type":33},"2026-03-17",{"date":146,"type":33},"2025-06-10",{"date":148,"type":21},"2026-12-31",{"name":150,"class":151},"Chinese Academy of Sciences","OTHER_GOV",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":160,"briefSummary":161,"conditions":162,"keywords":165,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":177,"locationsCount":61},"100571239","probiotics-in-pulmonaty-rehabilitation-for-copd-100571239","NCT06717659","Probiotics in Pulmonaty Rehabilitation for COPD","Probiotics in the Management of Pulmonary Rehabilitation for COPD: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Willing to sign a written informed consent form.\n* Diagnosed with pre-COPD or COPD stage I-IV according to the 2023 GOLD guidelines.\n* Undergoing pulmonary rehabilitation therapy for more than three months.\n\nExclusion Criteria:\n\n* Under 18 years old.\n* Diagnosed with neuromuscular diseases.\n* Experienced respiratory disease exacerbation requiring emergency care or hospitalization in the past three months.\n* Unable to cooperate with cardiopulmonary exercise testing.\n* Has other diseases or behavioral restrictions preventing participation in exercise training for over one year.\n* Assessed by a physician to have severe malnutrition or a significantly low BMI.",{"count":20,"type":21},[74],"This study aims to investigate various aspects of patients with chronic respiratory diseases undergoing pulmonary rehabilitation supplemented with probiotics. The focus will be on clinical physiological responses, functional performance, respiratory status assessments, nutritional status evaluations, body composition analyses, and biochemical blood parameters, with a primary emphasis on the anti-inflammatory response.",[163,28,164],"COPD (Chronic Obstructive Pulmonary Disease)","Body Composition Measurement",[166,167,168,169,170],"body composition","inflammation markers","nutritional supplementation","probiotics","chronic obstructive pulmonary disease","2026-02-25",{"date":173,"type":33},"2026-02-27",{"date":175,"type":33},"2024-12-05",{"date":148,"type":21},{"name":178,"class":39},"Fu Jen Catholic University",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":186,"enrollmentInfo":187,"targetDuration":4,"studyType":22,"phases":189,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":199,"locationsCount":61},"100614151","multi-strain-probiotic-effects-on-self-reported-constipation-100614151","NCT07275866","Multi-strain Probiotic Effects on Self-Reported Constipation","A Pilot Study of a Multi-Strain Liquid Probiotic in Individuals Self-reporting Constipation in the General Population.","Inclusion Criteria:\n\n1. Participant has provided written informed consent before participating in the study after being given a full description of the study and prior to any study-specific procedures being performed.\n2. Participant has Cleveland Clinic constipation score (CCCS) of 9-16 at screening call\n3. Participant is willing to discontinue all other therapies for constipation and undergo washout where applicable.\n4. Participant is a male or non-pregnant female and is 18-70 years of age\n5. If WOCBP participant is willing to adhere to one of the following methods of contraception:\n\n   i) Hormonal contraception e.g. the 'pill' or an implant ii) Intrauterine device (IUD) iii) Intrauterine hormone-releasing system (IUS) vi) Sexual abstinence (if it is in line with participants' preferred and usual lifestyle).\n\n   or has had a: v) Hysterectomy or has a: vi) Vasectomised partner\n6. Participant can communicate well with the Investigator and to comply with the requirements for the entire study.\n7. Participant has capacity to understand written English.\n8. Participant has a body mass index (BMI) of 18.5 - 39.9kg\u002Fm2 (bounds included).\n9. Participant agrees to follow all pre-test preparation for the ATMO capsule transit study.\n\nExclusion Criteria:\n\n1. Women who are pregnant and\u002For breastfeeding.\n2. Participants who are planning to significantly change their diet (e.g. weight loss program, becoming vegetarian) during the study period.\n3. Participant has had diarrhoea within 7 weeks of screening period.\n4. Prior abdominal surgery involving resection of the small or large bowel.\n5. Prior bariatric surgery involving resection of the stomach or by-pass procedures.\n6. Type 1 diabetes mellitus.\n7. Known organic or structural GI disease including:\n\n   * Coeliac disease\n   * Inflammatory bowel disease\n   * Diverticulitis\n   * Small bowel strictures\n8. Irritable bowel syndrome where the predominant symptom is pain (assessed via screening questions).\n9. Oropharyngeal dysphagia or difficulty swallowing capsules.\n10. Any other medical condition that the investigator deems may confound results or affect participants' safety in the study.\n11. Any use of prohibited medication that the participant cannot complete appropriate washout for.\n12. Insufficient knowledge of English to complete the daily bowel diary.\n13. Allergy to any component of the supplement, motility bar, lactulose or Zoe blue cookie.\n14. Participant is involved in this study as an investigator, sub-Investigator, study coordinator, other study staff, or Sponsor member.\n15. Previous use of the probiotic Symprove.","70 Years",{"count":188,"type":21},20,[74],"Constipation is a prevalent gastrointestinal condition. Beyond simple lifestyle measures (e.g. increasing fibre intake, hydration, levels of exercise), medical therapies are available for management. However, a sizeable number of sufferers are dissatisfied with drug treatments (either over-the-counter or prescribed), meaning there is an unmet need for alternative therapeutic strategies.\n\nPre, pro- and synbiotics have emerged as one alternative treatment, and a growing body of evidence now supports their use in a proportion of individuals with mild constipation. However, it is currently not possible to predict which individuals may benefit. A better understanding of an individuals' symptoms and underlying pathophysiology may allow for more targeted treatment.\n\nThe multistrain live bacterial food product (probiotic) being tested contains billions of live and active bacteria that has been shown to improve symptoms in the irritable bowel syndrome (IBS: which is 'constipation-predominant' in many). Notably, improvements ('completely resolved' or 'some positive difference') in bowel habit satisfaction, abdominal pain, bloating and urgency, as well as on quality of life have been shown after 4 or more weeks of this probiotc.\n\nThis study aims to have 20 participants with self-reported constipation to assess improvements in constipation symptoms, quality of life and measures of gut function.",[192,82,28],"Constipation","2025-12-10",{"date":195,"type":33},"2025-12-18",{"date":197,"type":33},"2025-10-03",{"date":91,"type":21},{"name":200,"class":39},"Dr Anthony Hobson",{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":208,"enrollmentInfo":209,"targetDuration":4,"studyType":22,"phases":210,"briefSummary":212,"conditions":213,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":222,"locationsCount":61},"100596582","phase-2-evaluate-the-efficacy-and-safety-of-probiotic-6600-as-an-adjuvant-therapy-for-colitis-100596582","NCT07047339","Evaluate the Efficacy and Safety of Probiotic 6600 as an Adjuvant Therapy for Colitis","A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Probiotic 6600 as an Adjuvant Therapy for Colitis","Inclusion Criteria:\n\n1. Ulcerative colitis (UC) : met the clinical diagnostic criteria of UC \"Chinese Guidelines for the Diagnosis and Treatment of Ulcerative Colitis (2023, Xi 'an)\", and modified Mayo score ≥4 points;\n2. Crohn's disease (CD) : met the clinical diagnostic criteria of CD \"Chinese Guidelines for the Diagnosis and Treatment of Crohn's Disease (2023, Guangzhou)\", and CDAI score ≥220;\n3. Colitis: clinical diagnosis of colitis and modified SCCAI score ≥3; 3.\n4. The age of signing the informed consent form was from 18 to 75 years old (including the cut-off value, male and female were not limited);\n5. Complete medical history;\n6. From the time of informed consent until 3 months after the last dose of dose, the participant committed to not having any plans to have children or to have any plans to donate sperm or eggs, and to voluntarily use non-pharmacologic contraception;\n7. Fully understand the content, process and possible adverse reactions of the trial, voluntarily participate in the trial, and sign the informed consent.\n\nExclusion Criteria:\n\n1. Taking prebiotics or probiotics in the past 2 weeks or allergic to intervention preparations;\n2. Short bowel syndrome, abdominal abscess, toxic megacolon, intestinal perforation, active fistula of digestive tract, severe intestinal stenosis with obstructive symptoms, suspected intestinal obstruction, total colectomy;\n3. Other autoimmune diseases, hematological diseases, tumors, acute infections, severe hepatic and renal insufficiency (ALT\\>2 times the upper limit of normal), severe diseases such as neutropenia, heart failure, organic heart disease, viral hepatitis B, liver cirrhosis, renal impairment (serum creatinine \\> 2mg\u002FdL or 177mmol\u002FL), AIDS And mental disorders;\n4. History of psychoactive substance abuse;\n5. A history of drug or other dependent substance abuse, or heavy alcohol consumption in the last 2 weeks (i.e. 28 standard units per week for men and 21 standard units per week for women (1 standard unit contains 14g of alcohol, such as 360mL of beer or 25mL of 40% spirits or 150mL of wine); Heavy drinkers during the trial;\n6. Pregnant or breastfeeding women, or planning to become pregnant in the next 6 months;\n7. Nervous system diseases such as Alzheimer's disease, stroke, Parkinson's disease;\n8. Participated in other clinical trials within the past 6 months;\n9. Incomplete medical record information (including gender, age, diagnostic information, colonoscopy results, pathological diagnosis results and other demographic data, etc.);\n10. Other investigators deemed ineligible for enrollment.","75 Years",{"count":49,"type":21},[24,211],"PHASE3","This study was conducted in two phases. In Phase I, 40 UC participants, 40 CD participants, and 40 colitis participants were randomly assigned in a 1:1 ratio to the experimental group and the control group, respectively. The study included a screening period (1 week), a double-blind treatment period (24 weeks), an exit examination (1 day), and a safety follow-up period (4 weeks). After providing informed consent, participants who met the inclusion criteria and those who did not meet the exclusion criteria were randomly assigned, in a 1:1 ratio, to receive either the trial (probiotic 6600 capsules) or the control group (placebo). The clinical remission rate (SCCAI score ≤2 and no single subscore \\>1) after 24 weeks of treatment was calculated. Mayo score ≤2 and no single subscore \\>1; CDAI score ≤2 and no single subscore \\>1) were used as the primary efficacy index.",[214,215,28],"Colitis","IBD (Inflammatory Bowel Disease)","2025-06-24",{"date":218,"type":33},"2025-07-02",{"date":220,"type":21},"2025-07-01",{"date":148,"type":21},{"name":223,"class":39},"Changhai Hospital"]